BALA CYNWYD, Pa., Jan. 8, 2009 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith, LLC announces that it is investigating the legal ramifications of the proposed acquisition of Indevus Pharmaceuticals ("Indevus" or the "Company") (Nasdaq:IDEV) by Endo Pharmaceuticals ("Endo"). Endo has offered Indevus shareholders $4.50 a share for their stock. The deal is valued at approximately $370 million. Endo claims that Indevus shareholders could earn up to $2.00 - 3.00 more per share if certain regulatory or sales milestones are reached within an approximately three year period. Indevus stock traded at over $6.70 a share in January 2008 and, as recently as May 2008, the stock traded at more than the current Endo offer price.
If you are an Indevus shareholder and wish to discuss the legal ramifications of the proposed acquisition by Endo, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at clients@brodsky-smith.com, or by calling toll free 877-LEGAL-90.